JP2020526483A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526483A5
JP2020526483A5 JP2019570045A JP2019570045A JP2020526483A5 JP 2020526483 A5 JP2020526483 A5 JP 2020526483A5 JP 2019570045 A JP2019570045 A JP 2019570045A JP 2019570045 A JP2019570045 A JP 2019570045A JP 2020526483 A5 JP2020526483 A5 JP 2020526483A5
Authority
JP
Japan
Prior art keywords
subject
csa
period
dose
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526483A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/040181 external-priority patent/WO2019006235A1/en
Publication of JP2020526483A publication Critical patent/JP2020526483A/ja
Publication of JP2020526483A5 publication Critical patent/JP2020526483A5/ja
Priority to JP2023040600A priority Critical patent/JP2023088944A/ja
Priority to JP2025121073A priority patent/JP2025165979A/ja
Pending legal-status Critical Current

Links

JP2019570045A 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法 Pending JP2020526483A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023040600A JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023040600A Division JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法

Publications (2)

Publication Number Publication Date
JP2020526483A JP2020526483A (ja) 2020-08-31
JP2020526483A5 true JP2020526483A5 (cg-RX-API-DMAC7.html) 2021-08-05

Family

ID=63013097

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019570045A Pending JP2020526483A (ja) 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法
JP2023040600A Pending JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A Pending JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023040600A Pending JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A Pending JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Country Status (22)

Country Link
US (4) US11576910B2 (cg-RX-API-DMAC7.html)
EP (2) EP4512470A3 (cg-RX-API-DMAC7.html)
JP (3) JP2020526483A (cg-RX-API-DMAC7.html)
CN (1) CN110996953A (cg-RX-API-DMAC7.html)
AU (2) AU2018290983B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019028046A2 (cg-RX-API-DMAC7.html)
CA (1) CA3068588A1 (cg-RX-API-DMAC7.html)
DK (1) DK3645002T3 (cg-RX-API-DMAC7.html)
ES (1) ES3008457T3 (cg-RX-API-DMAC7.html)
FI (1) FI3645002T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241729T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069805T2 (cg-RX-API-DMAC7.html)
LT (1) LT3645002T (cg-RX-API-DMAC7.html)
MA (1) MA49508B1 (cg-RX-API-DMAC7.html)
MD (1) MD3645002T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020000190A (cg-RX-API-DMAC7.html)
PL (1) PL3645002T3 (cg-RX-API-DMAC7.html)
PT (1) PT3645002T (cg-RX-API-DMAC7.html)
RS (1) RS66581B1 (cg-RX-API-DMAC7.html)
SI (1) SI3645002T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500067T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019006235A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
WO2021163172A1 (en) * 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
JP7832128B2 (ja) * 2020-06-15 2026-03-17 マイオカーディア,インク 心房機能不全の治療
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
IL302850A (en) * 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
CA3268270A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス, インコーポレイテッド キナゾリンジオン化合物およびその使用
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節If電流阻害剤の併用療法
AU2018214629A1 (en) 2017-02-06 2019-08-22 Acceleron Pharma Inc. Compositions and methods for treating heart failure
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
EP3599243B1 (en) 2018-07-26 2023-04-12 CVIE Therapeutics Limited 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
CN112118846B (zh) 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CA3157629A1 (en) 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
WO2021163172A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Similar Documents

Publication Publication Date Title
JP2023088944A5 (cg-RX-API-DMAC7.html)
FI3645002T3 (fi) Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla
JP2020529996A5 (cg-RX-API-DMAC7.html)
JP6309454B2 (ja) 癌の併用処置
JP2021059610A (ja) 処置法
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
JP2015057436A5 (cg-RX-API-DMAC7.html)
JP2013501224A5 (cg-RX-API-DMAC7.html)
JP2019534304A5 (cg-RX-API-DMAC7.html)
JP2020502261A5 (cg-RX-API-DMAC7.html)
JP2017513809A5 (cg-RX-API-DMAC7.html)
Patel et al. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations.
JP2017128610A (ja) 併用als療法
CN117529320A (zh) 用于治疗病毒感染的rock2抑制剂
WO2024081611A1 (en) Methods for treating heart failure by administering cardiac sarcomere activators
JP2019519544A5 (cg-RX-API-DMAC7.html)
CN116157119A (zh) 一种ARNi与钙离子拮抗剂的药物组合物与应用
EP2303259A1 (en) Dronedarone for the prevention of cardioversion
WO2014176549A2 (en) Vanoxerine for self-administration for terminating acute episodes of cardiac arrhythmia in mammals
WO2014134419A1 (en) Use of ikach blockers for the treatment of cardiac diseases
MX2022006404A (es) Composicion farmaceutica para el tratamiento de la enfermedad vascular pulmonar y/o disfuncion cardiaca en pacientes paliados con fontan.
JP2021091608A5 (cg-RX-API-DMAC7.html)
JP6028983B2 (ja) ビダラビンによる心房細動治療
US20230201313A1 (en) Methods of treating left ventricle hypertrophy
HK40125990A (en) Treatments for cushing's syndrome that do not significantly affect cardiac rhythms